Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CROMOLYN NASAL SPRAY | 2% | SOLUTION SPRAY | Actual shortage | 2017-08-13 | 2017-10-05 | 19051 |
| APO-CROMOLYN STERULES | 1% | SOLUTION | Actual shortage | 2017-08-13 | 2017-10-05 | 19054 |
| APO-CYCLOBENZAPRINE | 10MG | TABLET | Resolved | 2018-03-05 | 2018-04-14 | 41844 |
| APO-CYCLOBENZAPRINE | 10MG | TABLET | Resolved | 2024-05-03 | 2024-05-17 | 227091 |
| APO-CYCLOBENZAPRINE | 10MG | TABLET | Resolved | 2024-07-04 | 2024-09-27 | 232292 |
| APO-CYCLOSPORINE ORAL SOLUTION | 100MG | SOLUTION | Resolved | 2017-03-10 | 2018-09-09 | 241 |
| APO-DABIGATRAN | 110MG | CAPSULE | Resolved | 2022-11-20 | 2023-01-20 | 175318 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2023-02-23 | 2023-03-23 | 185492 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2023-04-14 | 2023-06-08 | 189659 |
| APO-DABIGATRAN | 110MG | CAPSULE | Resolved | 2019-06-26 | 2022-10-07 | 87509 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2020-08-19 | 2021-01-26 | 122473 |
| APO-DABIGATRAN | 75MG | CAPSULE | Resolved | 2024-06-13 | 2024-07-19 | 230477 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2024-06-14 | 2024-09-20 | 230558 |
| APO-DABIGATRAN | 110MG | CAPSULE | Resolved | 2024-06-14 | 2024-09-20 | 230561 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2024-07-12 | 2024-07-19 | 232842 |
| APO-DABIGATRAN | 150MG | CAPSULE | Actual shortage | 2024-10-24 | 2024-10-24 | 241059 |
| APO-DABIGATRAN | 110MG | CAPSULE | Actual shortage | 2024-11-15 | 2024-11-15 | 243170 |
| APO-DABIGATRAN | 110MG | CAPSULE | Resolved | 2024-12-05 | 2025-01-24 | 244888 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2024-02-09 | 2024-02-23 | 219149 |
| APO-DABIGATRAN | 110MG | CAPSULE | Resolved | 2024-02-09 | 2024-02-23 | 219152 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-TIMOP | 0.5% | SOLUTION | Discontinued | 2019-01-03 | 2019-01-03 | 70894 |
| APO-TIMOP GEL | Discontinued | 2019-01-03 | 2019-01-03 | 71020 | ||
| APO-TIMOP | Discontinued | 2019-01-02 | 2019-01-02 | 70818 | ||
| APO-TOLTERODINE | 1MG | TABLET | Discontinued | 2018-09-08 | 2019-01-17 | 60822 |
| APO-TOLTERODINE | 2MG | TABLET | Discontinued | 2018-09-08 | 2018-11-09 | 60825 |
| APO-TOLTERODINE | 2MG | TABLET | Discontinued | 2018-09-08 | 2019-06-12 | 60828 |
| APO-TRAZODONE TABLETS 100MG | 100MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60831 |
| APO-TRAZODONE TABLETS 50MG | 50MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60834 |
| APO-VALACYCLOVIR | 500MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60840 |
| APO-VALGANCICLOVIR | 450MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60843 |
| APO-VALPROIC ACID ORAL SOLUTION | 250MG | SOLUTION | Discontinued | 2023-09-26 | 2023-11-02 | 205310 |
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71029 | ||
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71032 | ||
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71035 | ||
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71038 | ||
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71044 | ||
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71048 | ||
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71051 | ||
| APO-VALSARTAN/HCTZ | 12.5MG 160MG | TABLET | Discontinued | 2019-01-03 | 2019-01-03 | 71054 |
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71057 |